PHI with Peritoneal Carcinomatosis
How does this condition affect your private health insurance?
Peritoneal carcinomatosis refers to the widespread dissemination of cancer cells within the peritoneum, the membrane lining the abdominal cavity. Most commonly, it's a metastatic complication arising from advanced gastrointestinal, ovarian, or appendiceal cancers, though it can rarely originate as primary peritoneal cancer. This aggressive condition often leads to symptoms like abdominal pain, distension, ascites (fluid accumulation), and bowel obstruction. Diagnosis typically involves imaging, exploratory surgery, and biopsy. Treatment is complex, often involving a multimodal approach with cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) or systemic chemotherapy, aiming to prolong survival and improve quality of life.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months for initial diagnosis and intensive treatment phase
Duration of Illness (Lifetime)
Chronic and life-limiting, typically months to a few years from diagnosis
Cost of Treatment (Initial)
Very high, often exceeding $100,000 for complex surgery and chemotherapy
Cost of Treatment (Lifetime)
Extremely high, potentially several hundred thousand dollars or more including ongoing treatments and palliative care
Mortality Rate
High to very high, as it signifies advanced cancer with a poor prognosis
Risk of Secondary Damages
Very high, including bowel obstruction, ascites, pain, malnutrition, surgical complications, and psychological distress
Probability of Full Recovery
Very low, complete cure is rare and typically only achieved in highly selected cases with minimal disease burden
Underlying Disease Risk
Extremely high (nearly 100%), as it is usually a metastatic spread from a primary cancer (e.g., colorectal, ovarian, gastric)